Publications
Featured Publications
Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Future Oncology
June 2023
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
All Publications
- All Publications
- Advanced Solid Tumors
- Cutaneous Melanoma
- Gastrointestinal Cancers
- Head & Neck Squamous Cell Carcinoma
- Lung Cancer
- Mucosal Melanoma
- Platinum Resistant Ovarian Cancer
- Renal Cell Carcinoma
Assessment of Safety and Immunologic Activity of Nemvaleukin Alfa in Patients With Advanced Solid Tumors Treated With Less Frequent Intravenous Dosing (ARTISTRY-3)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Subcutaneous Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Refractory Solid Tumors (ARTISTRY-2)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Preliminary Pharmacodynamic Characterization in Patients With Platinum-Resistant Ovarian Cancer Treated With Nemvaleukin in Combination With Pembrolizumab
American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer
October 2023
ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Future Oncology
June 2023
ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2023
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2023
A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies
American Association for Cancer Research (AACR) Annual Meeting
April 2023
A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies
American Association for Cancer Research (AACR) Annual Meeting
April 2023
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
European Congress on Gynaecological Oncology (ESGO) Congress
October 2022
Using Low Dose and Intermediate-affinity IL-2 receptor agonist (Nemvaleukin alfa) with XRT to address PD1 Resistance
American Society for Therapeutic Radiology and Oncology ( ASTRO) Annual Meeting
October 2022
ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022